Overview
Sotos syndrome, also known as cerebral gigantism, is a genetic overgrowth disorder characterized by excessive physical growth during the first years of life, distinctive facial features, and varying degrees of intellectual disability. The condition was first described by Dr. Juan Sotos in 1964. It is caused by mutations or deletions in the NSD1 gene (nuclear receptor binding SET domain protein 1) located on chromosome 5q35, which plays a critical role in regulating gene expression during development. The hallmark features of Sotos syndrome include pre- and postnatal overgrowth with increased height and head circumference (macrocephaly), a characteristic facial gestalt that includes a broad and prominent forehead, sparse frontotemporal hair, downslanting palpebral fissures, malar flushing, a long and narrow face, and a pointed chin. Advanced bone age is a consistent finding. Affected individuals typically experience developmental delay, particularly in motor and speech milestones, and intellectual disability that ranges from mild to severe, though some individuals have normal intelligence. Additional features may include hypotonia, behavioral problems (including features of autism spectrum disorder, anxiety, and ADHD), seizures, cardiac anomalies, renal anomalies, scoliosis, and an increased risk of certain tumors in childhood, though the overall cancer risk remains relatively low. There is no cure for Sotos syndrome, and management is supportive and symptom-based. Early intervention programs including speech therapy, occupational therapy, and physical therapy are important for optimizing developmental outcomes. Regular monitoring for potential complications such as scoliosis, cardiac defects, renal abnormalities, and seizures is recommended. Behavioral and educational support is often beneficial. Genetic counseling is advised for affected families, as most cases arise from de novo mutations, though autosomal dominant transmission from an affected parent can occur.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Sotos syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Sotos syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Sotos syndrome.
Community
No community posts yet. Be the first to share your experience with Sotos syndrome.
Start the conversation →Latest news about Sotos syndrome
No recent news articles for Sotos syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Sotos syndrome
What is Sotos syndrome?
Sotos syndrome, also known as cerebral gigantism, is a genetic overgrowth disorder characterized by excessive physical growth during the first years of life, distinctive facial features, and varying degrees of intellectual disability. The condition was first described by Dr. Juan Sotos in 1964. It is caused by mutations or deletions in the NSD1 gene (nuclear receptor binding SET domain protein 1) located on chromosome 5q35, which plays a critical role in regulating gene expression during development. The hallmark features of Sotos syndrome include pre- and postnatal overgrowth with increased
How is Sotos syndrome inherited?
Sotos syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Sotos syndrome typically begin?
Typical onset of Sotos syndrome is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Sotos syndrome?
2 specialists and care centers treating Sotos syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.